In Brief: Anika Therapeutics
This article was originally published in The Gray Sheet
Anika Therapeutics: Submits premarket approval application to FDA for its Orthovisc intra-articular injectable hyaluronic acid treatment for osteoarthritis of the knee. The PMA includes data on 226 patients treated with the product at 10 U.S. centers. Last month, Anika inked an agreement with Bristol-Myers Squibb's Zimmer subsidiary for marketing of Orthovisc in the U.S., Canada and "select Asia-Pacific markets" ("The Gray Sheet" Nov. 17, In Brief)...
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.